NUMECO Inc. (Medytox subsidiary) · Republic of Korea (Medytox Osong Plant III)
Newlux 100U is a next-generation botulinum toxin type A manufactured by NUMECO Inc., a subsidiary of Medytox Inc., at Medytox’s Osong Plant III in South Korea. Each single-use vial contains 100 units of botulinum toxin type A as freeze-dried (lyophilized) powder. Newlux is differentiated by NUMECO’s production process that excludes animal-derived raw materials, addressing potential allergic reactions caused by animal antigens. KFDA-approved in August 2023; included in 2024 Korean expert consensus guidelines for facial expression muscles (PubMed).
Why this product is different
Newlux is manufactured by NUMECO Inc., a wholly-owned subsidiary of Medytox Inc. operating at Medytox’s Osong Plant III — a third-generation manufacturing facility with output capacity several times that of Medytox’s older Ochang Plant I. The Newlux production process excludes animal-derived raw materials at every stage, addressing concerns about potential allergic reactions caused by animal antigens. This is a stronger animal-free claim than many competitor products that only remove animal-derived components from final formulation but use animal-derived materials during fermentation. Newlux received KFDA approval in August 2023 and was the subject of a 2024 Korean expert consensus publication in Toxins/PubMed providing clinical guidelines for facial expression muscle treatment.
Mechanism of action
Botulinum toxin type A is a presynaptic neuromuscular blocker. Following injection into target muscle, the toxin’s heavy chain binds to specific receptors on motor nerve terminals; the light chain is internalised into the nerve cytoplasm, where it enzymatically cleaves SNAP-25 — a SNARE complex protein required for acetylcholine vesicle fusion at the neuromuscular junction. Without SNAP-25, acetylcholine release into the synaptic cleft is blocked, the motor nerve cannot signal the muscle fibre to contract, and the targeted muscle relaxes. New axon terminals eventually sprout and restore neuromuscular signalling, at which point clinical effect wanes.
Specifications
Common application zones
Application zones below are common indications for which botulinum toxin type A is used by practitioners. Specific dosing per zone is determined by the treating practitioner based on individual patient anatomy and clinical judgment.
Contraindications
Frequently asked questions
Newlux 100U is a next-generation Korean botulinum toxin type A manufactured by NUMECO Inc. — a subsidiary of Medytox Inc. — at Medytox’s Osong Plant III. Each single-use vial contains 100 units of botulinum toxin type A as freeze-dried (lyophilized) powder for reconstitution. The production process excludes animal-derived raw materials.
Newlux is manufactured by NUMECO Inc., a wholly-owned subsidiary of Medytox Inc. Production takes place at Medytox’s Osong Plant III in Cheongju, North Chungcheong Province, South Korea — a third-generation manufacturing facility purpose-built for next-generation botulinum toxin products. NUMECO is sometimes spelled ‘Newmeco’ in some sources.
Yes. NUMECO Inc. is a wholly-owned subsidiary of Medytox Inc., the Korean biopharmaceutical company that also produces Meditoxin (Neuronox), Innotox, and Coretox. Newlux is the lead product of NUMECO and represents Medytox group’s next-generation manufacturing platform.
Newlux’s production process excludes animal-derived raw materials at every stage of manufacturing, addressing concerns about potential allergic reactions caused by animal antigens. This is a stronger animal-free claim than products that only remove animal-derived components from final formulation but use animal-derived materials during fermentation (such as casein-based culture media). Newlux uses non-animal-derived fermentation media throughout.
Common aesthetic application zones include glabellar lines, forehead lines, lateral canthal lines, masseter contouring, mentalis muscle, and platysma bands. The 2024 Korean expert consensus guideline published in Toxins/PubMed covers facial expression muscle treatment with Newlux. Therapeutic uses include hyperhidrosis and bruxism. Specific dosing per zone is determined by the treating practitioner.
Newlux 100U is the single-vial single-patient pack. Newlux 200U is a higher-unit-count vial for multi-zone single-patient sessions or multi-patient shared-vial protocols. Both share the same NUMECO proprietary working strain, freeze-drying process, and animal-derived-component-free production.
Both are produced by the Medytox group with animal-derived-component-free production processes. Coretox additionally removes complexing accessory proteins, leaving only the 150 kDa pure neurotoxin. Newlux retains the standard botulinum toxin complex but combines it with NUMECO’s next-generation animal-free production platform.
Both are produced by the Medytox group. Meditoxin (Neuronox) is Medytox’s classic first-generation product with conventional fermentation that uses animal-derived raw materials. Newlux is NUMECO’s next-generation product produced at Medytox Osong Plant III with animal-derived-component-free fermentation throughout.
Onset and duration vary with individual anatomy, muscle mass, metabolism, treatment zone, and dosing strategy. Practitioners can refer to the 2024 Korean expert consensus guideline (Ryu et al., Toxins, 2024) for clinical guidance specific to facial expression muscle treatment.
Store unopened vials at 2–8 °C, protected from light. Do not freeze. After reconstitution with 0.9% sterile saline, use within 24 hours when stored refrigerated. Discard any unused reconstituted product per institutional protocol.

Mike Henderson –
I get 100U for my underarms every summer. Newlux exceeded my expectations—I was bone dry by the third day. Some other brands I’ve tried tend to wear off quickly, but this one is still holding strong in month three. If you struggle with sweat, this is the one to get.